Nautilus Biotechnology, Inc. (NAUT)
NASDAQ
Delayed Data
Oct 23, 2026, 01:30 PM
Day's Range
2.5752 wk Range
0.8410Overview - NAUT - Nautilus Biotechnology, Inc.
Key Statistics
Valuation
Enterprise Value
356.09M
P/E (Trailing)
-6.90
P/E (Forward)
-4.37
PEG Ratio
0.82
Price / Sales (TTM)
2,167.02
Price / Book
3.14
EV / EBITDA
-5.80
Profitability
Gross Margin
-50.00%
Profit Margin
0.00%
Operating Margin
-8,296.31%
Return on Assets
-20.83%
Return on Equity
-36.20%
Ownership
Shares Outstanding
127.22M
Float
67.46M
Short % of Shares Outstanding
9.21%
Held by Insiders
32.01%
Held by Institutions
42.98%
Price stats
Beta
0.73
50-Day Avg
1.39
200-Day Avg
2.10
Analyst Consensus
4 analysts
Average price target
$ 3.83Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - NAUT - Nautilus Biotechnology, Inc.
Peers - NAUT - Nautilus Biotechnology, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
Profile Summary - NAUT - Nautilus Biotechnology, Inc.
About
Nautilus Biotechnology, Inc. is a life sciences company focused on proteomics, the large-scale study of proteins and their functions. Nautilus Biotechnology develops a platform technology designed to quantify and analyze the human proteome with high resolution, combining instrumentation, consumables, software, and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
